Table 1.
Cancer types with mutation incidence rates around or above 10% in the disordered driver gene of interest per total patients studied.
| Tumor Type (Name) | Implicated Gene Product | Malignancy | Incidence | Reference |
|---|---|---|---|---|
| Diffuse large B-cell lymphoma (ABC subtype) | CARD11 | malignant | 9.6–10.8% (7/73, 4/37) | [72,73] |
| Burkitt lymphoma | CCND3 | malignant | 14.6% (6/41) | [74] |
| Diffuse large B-cell lymphoma (ABC subtype) | CCND3 | malignant | 10.7% (3/28) | [74] |
| Diffuse large B-cell lymphoma (PCNS subtype) | CD79B | malignant | 31.6% (6/19) | [75] |
| Acute myeloid leukaemia | CEBPA | malignant | 15% (16/104) | [76] |
| Myelodysplasia and acute myeloblastic leukemia | CSF1R | malignant | 12.7% (14/110) | [77] |
| Endometrioid endometrial carcinoma (low-grade) | CTNNB1 | malignant | 87.0% (47/54) | [78] |
| Ovarian endometrioid carcinomas (low-grade) | CTNNB1 | malignant | 53.3% (16/30) | [79] |
| Hepatocellular carcinoma (HBV/HCV related) | CTNNB1 | malignant | 26% (32/122) | [80] |
| Desmoid tumor | CTNNB1 | benign | 73% (106/145) | [81] |
| Juvenile nasopharyngeal angiofibroma | CTNNB1 | benign | 75% (12/16) | [82] |
| Paraganglioma | EPAS1 | possibly malignant | 17% (7/41) | [83] |
| Adult granulosa cell tumors of the ovary | FOXL2 | malignant | 93–97% (52/56, 86/89) | [84,85] |
| Pediatric anaplastic astrocytoma/glioblastoma | H3F3A | malignant | 17.9–27.1% (5/28, 35/129) | [86] |
| Giant cell tumor of bone (stromal cell) | H3F3A | benign | 92% (49/53) | [87] |
| Chondroblastoma (stromal cell) | H3F3B | benign | 95% (73/77) | [87] |
| GIST | KIT | malignant | 47% (57/121) | [88] |
| Extrauterine leiomyoma and leiomyosarcoma | MED12 | (possibly) malignant | 19% (6/32) | [89] |
| Phyllodes tumor of breast | MED12 | possibly malignant | 49% (41/83) | [90] |
| Uterine leiomyoma | MED12 | benign | 70% (159/225) | [91] |
| Rhabdomyosarcoma | MYOD1 | malignant | 20% (10/49) | [92] |
| Esophageal squamous cell carcinoma | NFE2L2 | malignant | 9.6% (47/490) | [93] |
| B-cell progenitor acute lymphoblastic leukemia | PAX5 | malignant | 34–39% (40/117, 94/242) | [94,95] |
| Chronic myelomonocytic leukemia | SETBP1 | malignant | 25% (14/56) | [96] |
| Atypical Chronic Myeloid Leukemia | SETBP1 | malignant | 24.3% (17/70) | [97] |
| Chronic myelomonocytic leukaemia | SRSF2 | malignant | 47% (129/275) | [98] |
| Pituitary adenoma | USP8 | possibly malignant | 14% (6/42) | [99] |